Absci Corporation (ABSI)
| Bid | 2.33 |
| Market Cap | 304.33M |
| Revenue (ttm) | 5.02M |
| Net Income (ttm) | -114.23M |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -2.54 |
| Forward PE | -5.09 |
| Analyst | Buy |
| Ask | 2.7 |
| Volume | 2,998,872 |
| Avg. Volume (20D) | 5,710,285 |
| Open | 2.52 |
| Previous Close | 2.51 |
| Day's Range | 2.34 - 2.53 |
| 52-Week Range | 2.34 - 6.72 |
| Beta | 2.10 |
About ABSI
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington....
Analyst Forecast
According to 5 analyst ratings, the average rating for ABSI stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 192.89% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Absci Looks Cheap And Positioned For Growth With AMD's AI BackingAbsci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI's main drug candidate for IBD. However, ABS-201 for hair lo...